Literature DB >> 25895821

Advances in use of immunomodulatory agents--a rheumatology perspective.

Minyoung Her1, Arthur Kavanaugh2.   

Abstract

With the advent of biologic agents such as TNF inhibitors, the treatment paradigm for autoimmune systemic inflammatory diseases has progressed tremendously. Despite some distinct treatments, similarities exist in several aspects of the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis (RA), IBD and psoriasis. With a so-called treat-to-target strategy aiming at remission, the intensive and early application of disease-modifying antirheumatic drugs within a 'window of opportunity', and in combination with TNF inhibitors, has become the overarching principle of RA therapy. In this Perspective, the concept of treatment approaches using immunomodulatory agents and the latest advances of therapies in autoimmune systemic inflammatory diseases, especially RA, are overviewed from a rheumatology perspective to provide insights into possible approaches to the treatment of inflammatory gastrointestinal disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25895821     DOI: 10.1038/nrgastro.2015.65

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  62 in total

Review 1.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

2.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

Review 3.  Treatment of rheumatoid arthritis: a review including newer and experimental anti-inflammatory agents.

Authors:  R L Kaye; R E Pemberton
Journal:  Arch Intern Med       Date:  1976-09

4.  Patients with rheumatoid arthritis in clinical remission manifest persistent joint inflammation on histology and imaging studies.

Authors:  Allen Anandarajah; Ralf Thiele; Ellen Giampoli; Johnny Monu; Gwy-Suk Seo; Changyong Feng; Christopher T Ritchlin
Journal:  J Rheumatol       Date:  2014-10-01       Impact factor: 4.666

5.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

6.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

7.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

8.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Authors:  Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich
Journal:  Lancet       Date:  2008-07-16       Impact factor: 79.321

9.  The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.

Authors:  Rieke Alten; Hermann Gram; Leo A Joosten; Wim B van den Berg; Joachim Sieper; Siegfrid Wassenberg; Gerd Burmester; Piet van Riel; Maria Diaz-Lorente; Gerardus J M Bruin; Thasia G Woodworth; Christiane Rordorf; Yannik Batard; Andrew M Wright; Thomas Jung
Journal:  Arthritis Res Ther       Date:  2008-06-05       Impact factor: 5.156

10.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal:  Ann Rheum Dis       Date:  2014-03-04       Impact factor: 19.103

View more
  6 in total

1.  Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014).

Authors:  April M Jorge; Na Lu; Yuqing Zhang; Sharan K Rai; Hyon K Choi
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

2.  Rheumatoid arthritis: Do TNF inhibitors influence lymphoma development?

Authors:  Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

Review 3.  Demystifying the cytokine network: Mathematical models point the way.

Authors:  Penelope A Morel; Robin E C Lee; James R Faeder
Journal:  Cytokine       Date:  2016-12-03       Impact factor: 3.861

4.  High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.

Authors:  Jack T Stapleton; Nancy Wagner; Rebecca Tuetken; Abbie R Bellamy; Heather Hill; Sonnie Kim; Patricia L Winokur
Journal:  Vaccine       Date:  2020-04-12       Impact factor: 3.641

5.  Outcomes of immunomodulatory and biologic therapy in people living with HIV.

Authors:  Michael J Peluso; Jessica Chen; Sadie Munter; Asia Reed; Justin Teraoka; Ingrid Eshun-Wilson; Timothy J Henrich; Peter V Chin-Hong
Journal:  AIDS       Date:  2020-07-01       Impact factor: 4.177

Review 6.  Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives.

Authors:  Leonie E Burgers; Karim Raza; Annette H van der Helm-van Mil
Journal:  RMD Open       Date:  2019-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.